Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cipcal is a widely used nutritional supplement marketed by Cipla, primarily indicated for the prevention and treatment of calcium and vitamin D3 deficiencies. It typically contains a combination of calcium carbonate and cholecalciferol (vitamin D3). Calcium is essential for maintaining bone density and structural integrity, while vitamin D3 facilitates the intestinal absorption of calcium and regulates bone mineralization. It is commonly prescribed for conditions such as osteoporosis, osteomalacia, and during pregnancy or lactation when nutritional requirements are increased. The product is available in various strengths and formulations, including tablets and suspensions, to cater to different patient needs.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium carbonate + cholecalciferol (Cipla).